论文部分内容阅读
目的观察螺内酯联合胺碘酮治疗阵发性心房颤动的疗效。方法 64例阵发性心房颤动患者随机分为治疗组和对照组。治疗组34例,每日口服螺内酯20mg,胺碘酮0.2mg,对照组30例,每日口服胺碘酮0.2,共治疗2年。结果治疗组阵发性房颤再次发作5例(14.71%),明显低于对照组7例(23.33%),P<0.05;治疗组转为持续性或永久性房颤3例(8.82%),明显低于对照组5例(16.67%),P<0.05。结论螺内酯确实能够降低阵发性房颤再发率,减少持续性或永久性房颤的发生率。
Objective To observe the efficacy of spironolactone combined with amiodarone in the treatment of paroxysmal atrial fibrillation. Methods 64 patients with paroxysmal atrial fibrillation were randomly divided into treatment group and control group. The treatment group of 34 patients, daily oral spironolactone 20mg, amiodarone 0.2mg, control group of 30 patients, daily oral amiodarone 0.2, a total of 2 years. Results In the treatment group, 5 cases (14.71%) had recurrent paroxysmal atrial fibrillation, which was significantly lower than 7 cases (23.33%) in the control group (P <0.05). The treatment group was changed to continuous or permanent atrial fibrillation in 3 cases (8.82% , Which was significantly lower than that of the control group (5 cases, 16.67%), P <0.05. Conclusion Spironolactone can indeed reduce the recurrence rate of paroxysmal atrial fibrillation and reduce the incidence of persistent or permanent atrial fibrillation.